Table 1 |
||||||||
|
General data of patients combined with renal TMA and lupus nephritis |
||||||||
|
No. |
Age (years) |
Clinical diagnosis |
Pathological types |
CFH (μg/ml) |
ACL |
Anti-β2GP-1 |
ADAMTS-13 Activity (%) |
C4d deposition on vascular wall |
|
|
||||||||
|
1 |
25 |
LN |
IV-G(A/C) |
386.0 |
- |
- |
88 |
- |
|
2 |
38 |
LN |
IV-G(A/C) |
670.2 |
- |
- |
83 |
++ |
|
3 |
34 |
LN |
IV-G(A) |
166.8 |
- |
- |
70 |
+ |
|
4 |
45 |
LN+MHT |
IV-G(A/C) |
694.8 |
- |
- |
68 |
- |
|
5 |
28 |
LN |
IV-G(A/C) |
298.8 |
- |
- |
94 |
+ |
|
6 |
43 |
LN |
IV-G(A)+V |
642.8 |
- |
- |
75 |
- |
|
7 |
26 |
LN+Scleroderma |
IV-G(A) |
136.0 |
- |
- |
74 |
+ |
|
8 |
26 |
LN |
IV-G(A)+V |
112.8 |
- |
- |
95 |
- |
|
9 |
23 |
LN |
IV-G(A)+V |
385.4 |
- |
- |
91 |
+ |
|
10 |
27 |
LN+TTP-HUS |
IV-G(A/C) |
146.0 |
- |
- |
97 |
+ |
|
11 |
32 |
LN |
III(A/C)+V |
467.6 |
- |
- |
95 |
+ |
|
12 |
38 |
LN+MHT |
IV-G(A/C) |
251.6 |
- |
- |
98 |
- |
|
13 |
20 |
LN |
IV-G(A) |
362.4 |
- |
- |
98 |
- |
|
14 |
31 |
LN |
IV-G(A) |
551.2 |
- |
- |
71 |
- |
|
15 |
25 |
LN |
IV-G(A) |
567.4 |
- |
- |
85 |
+ |
|
16 |
19 |
LN |
IV-G(A) |
620.4 |
- |
- |
98 |
+ |
|
17 |
34 |
LN+TTP-HUS |
IV-G(A) |
365.6 |
- |
- |
89 |
- |
|
18 |
19 |
LN |
IV-S(A) |
457.0 |
- |
- |
89 |
- |
|
19 |
31 |
LN |
IV-G(A) |
491.4 |
- |
- |
97 |
- |
|
20 |
18 |
LN+APS |
IV-G(A)+V |
162.0 |
+ |
- |
45 |
+ |
|
21 |
30 |
LN+APS |
V |
707.2 |
- |
+ |
98 |
+ |
|
22 |
43 |
LN |
III(A/C)+V |
498.8 |
- |
- |
96 |
+ |
|
23 |
24 |
LN |
IV-G(A/C) |
222.4 |
- |
- |
96 |
+ |
|
24 |
35 |
LN |
IV-G(A/C) |
540.0 |
- |
- |
99 |
- |
|
25 |
40 |
LN |
IV-G(A/C) |
117.8 |
- |
- |
98 |
- |
|
26 |
21 |
LN |
III |
201.2 |
- |
- |
63 |
+ |
|
27 |
38 |
LN |
IV-G(A) |
672.6 |
- |
- |
88 |
+ |
|
28 |
52 |
LN |
IV-G(A/C) |
131.0 |
- |
- |
96 |
- |
|
29 |
37 |
LN |
V |
340.0 |
- |
- |
32 |
- |
|
30 |
27 |
LN |
IV-G(A) |
124.4 |
- |
- |
95 |
- |
|
31 |
18 |
LN |
IV-G(A/C) |
492.8 |
- |
- |
95 |
- |
|
32 |
15 |
LN |
IV-G(A) |
221.2 |
- |
- |
97 |
++ |
|
33 |
33 |
LN |
IV-G(A) |
374.0 |
- |
- |
80 |
+ |
|
34 |
15 |
LN |
IV-G(A) |
407.2 |
- |
- |
68 |
+ |
|
35 |
40 |
LN |
V |
434.2 |
- |
- |
96 |
- |
|
36 |
20 |
LN |
IV-G(A) |
627.6 |
- |
- |
97 |
+ |
|
|
||||||||
|
Note: The normal range of serum CFH was 561.3 ± 179.7 (381.6 to 741.0) μg/ml. The normal range of ADAMTS-13 activity was 95% (42% to 99%). Abbreviations: APS, anti-phospholipid syndrome; LN, lupus nephritis; MHT, malignant hypertension; TTP-HUS, thrombotic thrombocytopenic purpura-hemolytic uremic syndrome |
||||||||
|
Song et al. Arthritis Research & Therapy 2013 15:R12 doi:10.1186/ar4142 |
||||||||
